Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAL-0951 vs rHuEPO in Anemic CKD Patients on Hemodialysis
NCT06720025Phase 3Completed
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Start
- Sep 2023
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of enarodustat in anemia of chronic kidney disease (CKD-A) (2 arms), sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd. Primary endpoint: Hemoglobin level at 24 weeks. Started Sep 2023; status: completed.
02
Drugs
enarodustat
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT06720025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06720025.